efatutazone

Phase 2Small molecule

AAlliance for Clinical Trials in Oncology

efatutazone is one of 43 small molecule programs targeting Myxoid Liposarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myxoid LiposarcomaActive, not recruiting

Thyroid CancerActive, not recruiting

Myxoid LiposarcomaPhase 2

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Sutent

Pfizer

Phase 2

3 5

Yervoy

Bristol-Myers Squibb

Phase 2

2 6

Stivarga

Bayer

Phase 2

1 7

Mektovi

Pfizer

Phase 2

1 8

Iressa

AstraZeneca

Phase 2

1 9

Actos

Takeda

Phase 2

1 10

Cotellic

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02152137·19 enrolled

Myxoid Liposarcoma1 trial

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02249949·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for efatutazone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — efatutazone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for efatutazone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlliance for Clinical Trials in Oncology

efatutazone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Cancer1 trial

Myxoid Liposarcoma1 trial

References

Drug Info

Quick Facts

Related News